Soluble ephrin a1 is necessary for the growth of HeLa and SK-BR3 cells

Cancer Cell International

Volumn 10, Issue , 2010, Pages

  Alford, Spencer ^a   Watson Hurthig, Adam ^b   Scott, Nadia ^b   Carette, Amanda ^b   Lorimer, Heather ^b   Bazowski, Jessa ^b   Howard, Perry L ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF VICTORIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN A1; EPHRIN A2;

ARTICLE; CELL ADHESION; CELL COMMUNICATION; CELL CULTURE; CELL GROWTH; CELL LINE; CELL MEMBRANE; CELL SURFACE; CELL TRANSFORMATION; CULTURE MEDIUM; HELA CELL; HUMAN; PROTEIN EXPRESSION; RNA INTERFERENCE;

EID: 77958476450     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-10-41     Document Type: Article

References (40)

1. Gale NW, Holland SJ, Valenzuela DM, Flenniken A, Pan L, Ryan TE, Henkemeyer M, Strebhardt K, Hirai H, Wilkinson DG, et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 1996, 17:9-19. 10.1016/S0896-6273(00)80276-7, 8755474.
2. Himanen JP, Chumley MJ, Lackmann M, Li C, Barton WA, Jeffrey PD, Vearing C, Geleick D, Feldheim DA, Boyd AW, et al. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nat Neurosci 2004, 7:501-509. 10.1038/nn1237, 15107857.
3. Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 2008, 6:1795-1806. 10.1158/1541-7786.MCR-08-0244, 19074825.
4. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001, 61:2301-2306.
5. Ireton RC, Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 2005, 5:149-157. 10.2174/1568009053765780, 15892616.
6. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ, Kinch MS. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999, 41:275-280. 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T, 10544301.
7. Easty DJ, Guthrie BA, Maung K, Farr CJ, Lindberg RA, Toso RJ, Herlyn M, Bennett DC. Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res 1995, 55:2528-2532.
8. Kinch MS, Carles-Kinch K. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis 2003, 20:59-68. 10.1023/A:1022546620495, 12650608.
9. Kinch MS, Moore MB, Harpole DH. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003, 9:613-618.
10. Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M, et al. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 2008, 7:1098-1103. 2705979, 18443431.
11. Sulman EP, Tang XX, Allen C, Biegel JA, Pleasure DE, Brodeur GM, Ikegaki N. ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics 1997, 40:371-374. 10.1006/geno.1996.4569, 9119409.
12. Rosenberg IM, Goke M, Kanai M, Reinecker HC, Podolsky DK. Epithelial cell kinase-B61: an autocrine loop modulating intestinal epithelial migration and barrier function. Am J Physiol 1997, 273:G824-G832.
13. Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 2008, 118:64-78. 10.1172/JCI33154, 2129239, 18079969.
14. Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 2005, 19:1884-1886.
15. Guo H, Miao H, Gerber L, Singh J, Denning MF, Gilliam AC, Wang B. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res 2006, 66:7050-7058. 10.1158/0008-5472.CAN-06-0004, 16849550.
16. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R, Kinch MS. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 1999, 10:629-638.
17. Fang WB, Ireton RC, Zhuang G, Takahashi T, Reynolds A, Chen J. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci 2008, 121:358-368. 10.1242/jcs.017145, 18198190.
18. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 2006, 5:228-233. 10.4161/cbt.5.2.2510, 16481735.
19. Miura K, Nam JM, Kojima C, Mochizuki N, Sabe H. EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell-cell contacts. Mol Biol Cell 2009, 20:1949-1959. 10.1091/mbc.E08-06-0549, 2663931, 19193766.
20. Cui XD, Lee MJ, Yu GR, Kim IH, Yu HC, Song EY, Kim DG. EFNA1 ligand and its receptor EphA2: Potential biomarkers for hepatocellular carcinoma. Int J Cancer 2010, 126(4):940-9.
21. Bartley TD, Hunt RW, Welcher AA, Boyle WJ, Parker VP, Lindberg RA, Lu HS, Colombero AM, Elliott RL, Guthrie BA, et al. B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature 1994, 368:558-560. 10.1038/368558a0, 8139691.
22. Easty DJ, Hill SP, Hsu MY, Fallowfield ME, Florenes VA, Herlyn M, Bennett DC. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999, 84:494-501. 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.0.CO;2-O, 10502726.
23. Potla L, Boghaert ER, Armellino D, Frost P, Damle NK. Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells. Cancer Lett 2002, 175:187-195. 10.1016/S0304-3835(01)00613-9, 11741747.
24. Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS, Kinch M, Wu L, Dhariwal J, Mohammed SI. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 2006, 12:353-360. 10.1158/1078-0432.CCR-05-1505, 16428472.
25. Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M, Duffy S, Lincoln D, Boyle G, Parsons PG, Boyd AW. Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer 2006, 6(144). 1501040, 16737551.
26. Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 2005, 3:541-551. 10.1158/1541-7786.MCR-05-0056, 16254188.
27. Liu DP, Wang Y, Koeffler HP, Xie D. Ephrin-A1 is a negative regulator in glioma through down-regulation of EphA2 and FAK. Int J Oncol 2007, 30:865-871.
28. Nakamura R, Kataoka H, Sato N, Kanamori M, Ihara M, Igarashi H, Ravshanov S, Wang YJ, Li ZY, Shimamura T, et al. EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci 2005, 96:42-47. 10.1111/j.1349-7006.2005.00007.x, 15649254.
29. Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS, Mittal SK. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther 2004, 11:757-766. 10.1038/sj.cgt.7700761, 15359289.
30. Shi L, Itoh F, Itoh S, Takahashi S, Yamamoto M, Kato M. Ephrin-A1 promotes the malignant progression of intestinal tumors in Apc(min/+) mice. Oncogene 2008, 27(23):3265-73. 10.1038/sj.onc.1210992, 18246128.
31. Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, Debinski W. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene 2008, 27:7260-7273. 10.1038/onc.2008.328, 18794797.
32. Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM. Role of B61, the ligand for the Eck receptor tyrosine kinase in TNF-alpha-induced angiogenesis. Science 1995, 268:567-569. 10.1126/science.7536959, 7536959.
33. Holzman LB, Marks RM, Dixit VM. A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol Cell Biol 1990, 10:5830-5838. 361366, 2233719.
34. Davis S, Gale NW, Aldrich TH, Maisonpierre PC, Lhotak V, Pawson T, Goldfarb M, Yancopoulos GD. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 1994, 266:816-819. 10.1126/science.7973638, 7973638.
35. Alford SC, Bazowski J, Lorimer H, Elowe S, Howard PL. Tissue transglutaminase clusters soluble A-type ephrins into functionally active high molecular weight oligomers. Exp Cell Res 2007, 313:4170-4179. 10.1016/j.yexcr.2007.07.019, 17707797.
36. Peehl DM, Stanbridge EJ. Anchorage-independent growth of normal human fibroblasts. Proc Natl Acad Sci USA 1981, 78:3053-3057. 10.1073/pnas.78.5.3053, 319498, 6942414.
37. Orsulic S, Kemler R. Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J Cell Sci 2000, 113(Pt 10):1793-1802.
38. Holland SJ, Gale NW, Gish GD, Roth RA, Songyang Z, Cantley LC, Henkemeyer M, Yancopoulos GD, Pawson T. Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO J 1997, 16:3877-3888. 10.1093/emboj/16.13.3877, 1170012, 9233798.
39. Holland SJ, Gale NW, Mbamalu G, Yancopoulos GD, Henkemeyer M, Pawson T. Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands. Nature 1996, 383:722-725. 10.1038/383722a0, 8878483.
40. Dalva MB, Takasu MA, Lin MZ, Shamah SM, Hu L, Gale NW, Greenberg ME. EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell 2000, 103:945-956. 10.1016/S0092-8674(00)00197-5, 11136979.